Advertisement FDA approves Watson generic contraceptive pill - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

FDA approves Watson generic contraceptive pill

The US Food and Drug Administration (FDA) has approved Watson Laboratories' Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.09mg/0.02mg.

Watson‘s Levonorgestrel and Ethinyl Estradiol Tablets, USP, 0.09mg/0.02mg are the generic version of Lybrel Tablets of Pfizer.

Lybrel is indicated for the prevention of pregnancy in women who choose to use oral contraceptives as a method of contraception.

Lybrel is a progesterone and estrogen combination birth control pill which works by preventing ovulation, thickening the mucus in the cervix and changing the lining of the uterus.